A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2017
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Asthenia
- Focus Therapeutic Use
- Sponsors Longeveron
- 06 Sep 2017 According to the Longeveron media release, this trial is being conducted pursuant to an Investigational New Drug Application (IND) in conformance with U.S. Food & Drug Administration (FDA) regulations.
- 06 Sep 2017 According to the Longeveron media release, first patient has been treated in this trial.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.